Chemoprevention of prostate cancer: An updated view

Eric A. Klein, Ian M. Thompson

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: To place chemoprevention of prostate cancer in current clinical context. Methods: Review of recently published updates of large, randomized, controlled trials of primary chemoprevention of prostate cancer. Results: With extended post-intervention follow-up, SELECT demonstrated a 17% increased risk of prostate cancer relative to placebo in the vitamin E alone arm. Two other trials in men with high-grade PIN demonstrated no effect of selenium alone or in combination with soy and lycopene. Trials of 5α-reductase inhibitors show an approximate 25% relative risk reduction in men at average risk and in those with an "elevated" PSA and prior negative biopsy, but adoption of these agents in clinical practice has been limited by concerns over an apparently increased risk of high-grade disease. Conclusions: Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity. Neither selenium nor vitamin E prevents prostate cancer. The benefit/risk ratio for 5α-reductase inhibitors can be improved by limiting their use to men at high risk.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalWorld Journal of Urology
Volume30
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Chemoprevention
Prostatic Neoplasms
Selenium
Vitamin E
Oxidoreductases
Risk Reduction Behavior
Primary Prevention
Randomized Controlled Trials
Odds Ratio
Placebos
Morbidity
Biopsy

Keywords

  • 5α-Reductase inhibitors
  • Chemoprevention
  • Prostate cancer
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Urology

Cite this

Chemoprevention of prostate cancer : An updated view. / Klein, Eric A.; Thompson, Ian M.

In: World Journal of Urology, Vol. 30, No. 2, 04.2012, p. 189-194.

Research output: Contribution to journalArticle

Klein, Eric A. ; Thompson, Ian M. / Chemoprevention of prostate cancer : An updated view. In: World Journal of Urology. 2012 ; Vol. 30, No. 2. pp. 189-194.
@article{b3cc98274206473aa3db9ded9a8eb400,
title = "Chemoprevention of prostate cancer: An updated view",
abstract = "Objectives: To place chemoprevention of prostate cancer in current clinical context. Methods: Review of recently published updates of large, randomized, controlled trials of primary chemoprevention of prostate cancer. Results: With extended post-intervention follow-up, SELECT demonstrated a 17{\%} increased risk of prostate cancer relative to placebo in the vitamin E alone arm. Two other trials in men with high-grade PIN demonstrated no effect of selenium alone or in combination with soy and lycopene. Trials of 5α-reductase inhibitors show an approximate 25{\%} relative risk reduction in men at average risk and in those with an {"}elevated{"} PSA and prior negative biopsy, but adoption of these agents in clinical practice has been limited by concerns over an apparently increased risk of high-grade disease. Conclusions: Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity. Neither selenium nor vitamin E prevents prostate cancer. The benefit/risk ratio for 5α-reductase inhibitors can be improved by limiting their use to men at high risk.",
keywords = "5α-Reductase inhibitors, Chemoprevention, Prostate cancer, Selenium, Vitamin E",
author = "Klein, {Eric A.} and Thompson, {Ian M.}",
year = "2012",
month = "4",
doi = "10.1007/s00345-011-0822-9",
language = "English (US)",
volume = "30",
pages = "189--194",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Chemoprevention of prostate cancer

T2 - An updated view

AU - Klein, Eric A.

AU - Thompson, Ian M.

PY - 2012/4

Y1 - 2012/4

N2 - Objectives: To place chemoprevention of prostate cancer in current clinical context. Methods: Review of recently published updates of large, randomized, controlled trials of primary chemoprevention of prostate cancer. Results: With extended post-intervention follow-up, SELECT demonstrated a 17% increased risk of prostate cancer relative to placebo in the vitamin E alone arm. Two other trials in men with high-grade PIN demonstrated no effect of selenium alone or in combination with soy and lycopene. Trials of 5α-reductase inhibitors show an approximate 25% relative risk reduction in men at average risk and in those with an "elevated" PSA and prior negative biopsy, but adoption of these agents in clinical practice has been limited by concerns over an apparently increased risk of high-grade disease. Conclusions: Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity. Neither selenium nor vitamin E prevents prostate cancer. The benefit/risk ratio for 5α-reductase inhibitors can be improved by limiting their use to men at high risk.

AB - Objectives: To place chemoprevention of prostate cancer in current clinical context. Methods: Review of recently published updates of large, randomized, controlled trials of primary chemoprevention of prostate cancer. Results: With extended post-intervention follow-up, SELECT demonstrated a 17% increased risk of prostate cancer relative to placebo in the vitamin E alone arm. Two other trials in men with high-grade PIN demonstrated no effect of selenium alone or in combination with soy and lycopene. Trials of 5α-reductase inhibitors show an approximate 25% relative risk reduction in men at average risk and in those with an "elevated" PSA and prior negative biopsy, but adoption of these agents in clinical practice has been limited by concerns over an apparently increased risk of high-grade disease. Conclusions: Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity. Neither selenium nor vitamin E prevents prostate cancer. The benefit/risk ratio for 5α-reductase inhibitors can be improved by limiting their use to men at high risk.

KW - 5α-Reductase inhibitors

KW - Chemoprevention

KW - Prostate cancer

KW - Selenium

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=84859440444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859440444&partnerID=8YFLogxK

U2 - 10.1007/s00345-011-0822-9

DO - 10.1007/s00345-011-0822-9

M3 - Article

C2 - 22238120

AN - SCOPUS:84859440444

VL - 30

SP - 189

EP - 194

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -